Clinical trials: Refractory Brain Neoplasm
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Pediatric Cancer
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
- Trial name
- NCT07773454
- Testing
- Zanzalintinib
- Volunteers
- 18 people
- Sponsor
- Exelixis
Breast Cancer, Brain Cancer
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors.
- Conditions
- Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers
- Trial name
- NCT02045368
- Testing
- IGF-Methotrexate conjugate
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- IGF Oncology, LLC
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
ONC201 in Pediatric H3 K27M Gliomas
This was a Phase 1, open label, multicenter, 8-arm, dose escalation study of dordaviprone (ONC201) in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent/refractory H3 K27M-mutant…
- Trial name
- NCT03416530
- Testing
- Dordaviprone (ONC201)
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Glioblastoma Multiforme, Glioblastoma
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if appropriate), standard of care chemo-radiation with…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, GBM
- Trial name
- STAR-3 (NCT03149575)
- Testing
- VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- DelMar Pharmaceuticals, Inc.
Glioma, Glioblastoma
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT01478178
- Testing
- VAL-083 (Dianhydrogalactitol)
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Kintara Therapeutics, Inc.
Carcinoid Tumor, Acromegaly
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
- Trial name
- NCT00446082
- Testing
- Pasireotide
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Brain Neoplasms
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.
- Trial name
- NCT00393965
- Testing
- MPC-6827
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Myrexis Inc.
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Glioblastoma, Diffuse Intrinsic Pontine Glioma
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
This is a phase 1/2, uncontrolled, open-label, multicenter study in patients with recurrent and relapsed diffuse intrinsic pontine glioma, glioblastoma, or grade III or IV glioma.
- Trial name
- NCT02750891
- Testing
- DSP-7888
- Where
- 6 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Anaplastic Astrocytoma, Glioblastoma
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma…
- Trial name
- SAPPHIRE (NCT00761280)
- Testing
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009
- Where
- 68 sites in United States, Argentina and 14 more
- Volunteers
- 27 people
- Sponsor
- Isarna Therapeutics GmbH
Brain and Central Nervous System Tumors
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or…
- Trial name
- NCT03150862
- Testing
- Pamiparib, TMZ, Radiation
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 116 people
- Sponsor
- BeiGene USA, Inc.
Diffuse Astrocytoma, Anaplastic Astrocytoma
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high…
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT02684058
- Testing
- Dabrafenib, trametinib, Carboplatin
- Where
- 57 sites in United States, Argentina and 18 more
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Neuroblastoma
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
- Trial name
- NCT04106219
- Testing
- LY3295668 Erbumine, Topotecan, Cyclophosphamide
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Malignant Glioma of Brain, Colorectal Carcinoma
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Malignant Glioma of Brain, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT02617134
- Testing
- anti-MUC1 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Glioblastoma Multiforme, Glioma
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly…
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02052648
- Testing
- Indoximod, Temozolomide, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- NewLink Genetics Corporation